Bruce Booth Sells 55,985 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Key Points

• Bruce Booth, Director of Sionna Therapeutics, sold 55,985 shares of stock on October 20th, totaling approximately $1.8 million, resulting in a 7.39% decrease in his ownership.
• Sionna Therapeutics shares saw a slight increase of 0.8%, reaching a price of $32.20 with a trading volume of 222,456 shares.
• Recent analyst reports on Sionna Therapeutics show a consensus rating of "Moderate Buy" with a target price of $38.00, indicating positive outlooks from multiple firms.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 55,985 shares of the firm's stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $32.09, for a total value of $1,796,558.65. Following the sale, the director directly owned 701,985 shares in the company, valued at approximately $22,526,698.65. This trade represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.35, for a total value of $5,475,561.00.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.37, for a total value of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $372,383.28.

Sionna Therapeutics Stock Up 0.8%

Shares of Sionna Therapeutics stock traded up $0.27 on Monday, reaching $32.20. The company's stock had a trading volume of 222,456 shares, compared to its average volume of 325,019. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $34.00. The stock has a 50-day moving average price of $25.76 and a 200-day moving average price of $18.76.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.27.

Analyst Upgrades and Downgrades

SION has been the subject of a number of recent analyst reports. Jones Trading initiated coverage on Sionna Therapeutics in a research report on Monday, September 8th. They issued a "buy" rating and a $46.00 price objective for the company. Raymond James Financial began coverage on Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $45.00 price target on the stock. Wall Street Zen raised Sionna Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Royal Bank Of Canada began coverage on Sionna Therapeutics in a research note on Wednesday, September 3rd. They issued a "sector perform" rating and a $22.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sionna Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics during the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Sionna Therapeutics during the second quarter worth $45,000. Virtus Investment Advisers LLC acquired a new position in Sionna Therapeutics during the second quarter worth $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Sionna Therapeutics during the second quarter worth $117,000. Finally, New York State Common Retirement Fund acquired a new position in Sionna Therapeutics during the second quarter worth $118,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.